Drug Trial Radar · NCT05766501
A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)
Last checked: Nov 19, 2026Latest source record: Dec 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
641
Actual
Start
Mar 17, 2023
Primary completion
Oct 16, 2025
Study completion Sep 6, 2028
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and tolerability of DOR/ISL in adult participants with HIV-1 who had been previously treated with DOR/ISL in earlier clinical studies. There are no formal hypotheses to be tested in this study.
Conditions
- HIV Infection
Interventions
DOR/ISLDrug
FDC tablet of 100 mg doravirine (DOR)/0.25 mg islatravir (ISL) taken once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with One or More Adverse Event (AE)Time frame: Up to 96 Weeks
- Percentage of participants who Discontinue Study Intervention Due to an AETime frame: Up to 96 Weeks
Locations
95 sites in 15 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham-UAB 1917 Research Clinic ( Site 3104)
Birmingham, Alabama
Pueblo Family Physicians ( Site 3102)
Phoenix, Arizona
Pacific Oaks Medical Group ( Site 3123)
Beverly Hills, California
Kaiser Permanente ( Site 3124)
Los Angeles, California
Ruane Clinical Research Group, Inc ( Site 3126)
Los Angeles, California
Mills Clinical Research ( Site 3114)
Los Angeles, California
University of California Davis Health-Internal Medicine: Infectious Diseases ( Site 3137)
Sacramento, California
Georgetown University Medical Center ( Site 3130)
Washington D.C., District of Columbia
Therafirst Medical Center ( Site 3110)
Fort Lauderdale, Florida
Midway Immunology and Research Center ( Site 3117)
Ft. Pierce, Florida
AHF The Kinder Medical Group ( Site 3108)
Miami, Florida
Floridian Clinical Research, LLC ( Site 3133)
Miami Lakes, Florida
Orlando Immunology Center ( Site 3106)
Orlando, Florida
Bliss Healthcare Services ( Site 3115)
Orlando, Florida
CAN Community Health - Sarasota ( Site 3118)
Sarasota, Florida
Triple O Research Institute, P.A ( Site 3116)
West Palm Beach, Florida
Augusta University-Infectious Diseases ( Site 3135)
Augusta, Georgia
Infectious Disease Specialists of Atlanta ( Site 3128)
Decatur, Georgia
Mercer university, Department of internal medicine-Clinical Research ( Site 3129)
Macon, Georgia
Chatham County Health Department - Chatham CARE Center-Infectious Disease ( Site 3105)
Savannah, Georgia
KC CARE Health Center ( Site 3103)
Kansas City, Missouri
ID Care ( Site 3131)
Hillsborough, New Jersey
Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center ( Site 3134)
New York, New York
Penn Medicine: University of Pennsylvania Health System-Perelman Center for Advanced Medicine ( Site
Philadelphia, Pennsylvania
St Hope Foundation ( Site 3121)
Bellaire, Texas
North Texas Infectious Diseases Consultants, P.A ( Site 3100)
Dallas, Texas
Texas Centers for Infectious Disease Associates ( Site 3111)
Fort Worth, Texas
The Crofoot Research Center ( Site 3101)
Houston, Texas
DCOL Center for Clinical Research ( Site 3119)
Longview, Texas
Private Practice - Dr. Peter Shalit ( Site 3120)
Seattle, Washington
Multicare Institute for Research and Innovation ( Site 3127)
Spokane, Washington
Helios Salud ( Site 1002)
Buenos Aires, Argentina
Fundación Huésped ( Site 1001)
Buenos Aires, Argentina
Fundación IDEAA ( Site 1005)
Buenos Aires, Argentina
Instituto Oulton ( Site 1004)
Córdoba, Córdoba Province, Argentina
Instituto CAICI SRL ( Site 1003)
Rosario, Santa Fe Province, Argentina
Holdsworth House Medical Practice ( Site 1100)
Darlinghurst, New South Wales, Australia
St Vincent's Hospital-IBAC ( Site 1103)
Sydney, New South Wales, Australia
Holdsworth House Medical Practice - Brisbane ( Site 1101)
Brisbane, Queensland, Australia
Prahran Market Clinic ( Site 1102)
Melbourne, Victoria, Australia
Showing 40 of 95 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.